Altre lingue Kymera Therapeutics, Inc.

Azioni

KYMR

US5015751044

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
35,21 ^USD	-1,40%		+4,30%	+38,30%

23/04	KYMERA THERAPEUTICS, INC. : Oppenheimer ancora positivo	ZM
08/04	Kymera Therapeutics, Inc. annuncia presentazioni scientifiche al Meeting annuale dell'Associazione Americana per la Ricerca sul Cancro 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2	13:00
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting	08/04
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board	01/04
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing	14/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	11/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting	08/03
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics to Participate in Upcoming March Investor Conferences	28/02
Kymera Therapeutics Q4 Net Loss Narrows, Collaboration Revenue Rises	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Kymera Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update	22/02
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22	15/02
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference	31/01
Kymera Therapeutics Insider Sold Shares Worth $300,470, According to a Recent SEC Filing	24/01
Kymera Therapeutics Raises $316.2 Million From Offering, Outlines Cash Runway Guidance	09/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kymera Therapeutics, Inc.

Azioni

KYMR

US5015751044

Altre lingue

Filtri